Merck

KEYTRUDA

Manufacturer:

Merck

Keytruda HCPCS:

J9271

HCPCS Code Descriptor:

Injection, pembrolizumab, 1 mg

Category:

J Code

Keytruda NDCs:

00006-3026-02, 00006-3026-04

Primary Type:

Oncology

Generic/Specialty Status:

Single-Source

Package Type:

Vial

Route of Administration:

Intravenous

Potential NDC Listing Errors:

Our team has identified potential listing errors/discrepancies with the following NDCs:

00006-3026-04

About Keytruda:

KEYTRUDA is an Oncology drug manufactured by Merck and administered via the Intravenous route of administration. The J Code: J9271 is aligned to the drug KEYTRUDA.

Keytruda is a cancer drug that is used to treat numerous types of cancer and can be used by itself or with other cancer medications. This medication works by stopping the growth of the cancer cells. Keytruda is administered by infusion into the vein over the course of at least thirty minutes. Keytruda is manufactured by Merck Sharp & Dohme Corporation and is a branded drug. Patient assist programs for Keytruda can be found through Merck.

ACCESS PRICING AND MORE BY REGISTERING

J9271 Added Date:

January 1, 2016

J9271 Effective Date:

January 1, 2016

J9271 Termination Date:

HCPCS Active

Keytruda billing and coding information can be found through Merck at the link below:
Keytruda patient assistance information can be found through The Merck Access Program at the URL: https://www.merckaccessprogram-keytruda.com/hcc/
KEYTRUDA prescribing information can be found at the link below:
Information regarding KEYTRUDA’s side effects can be found at MedlinePlus